Connect with us


Study finds cell behaviour as cause behind resistance in neuroblastoma




One of the causes of resistance of neuroblastoma to chemotherapy has been discovered by researchers. The findings have implications for how treatments in the future should be developed.

The study was conducted by Lund University in Sweden and the study results have been published in Science Advances.

Neuroblastoma is an aggressive cancer of the sympathetic nervous system, particularly the adrenal gland. Despite intensive treatment with chemotherapy, the disease can be difficult to cure and the prognosis is poor for children with the aggressive variant. One of the reasons is that the tumor often develops drug resistance. In order to understand what happens when the tumor becomes resistant, good disease models are needed to mimic the complex drug treatment given to patients today:

“The tumors of patients with neuroblastoma are very different and it is difficult to produce a representative model of many patients. This type of challenge often limits medical research,” explains the first author of the study, Adriana Manas, researcher on the childhood cancer at Lund University. .

However, researchers have now succeeded in developing a mouse model with human neuroblastoma tumor cells, which can track the mechanisms that occur when certain tumor cells develop drug resistance.

“What happens is that the tumor cells change to mimic embryonic cells from the fetal development stage. These embryonic tumor cells are more resistant to chemotherapy,” says research group leader Daniel Bexell, who has led the study.

It has long been known that genetic changes are crucial for neuroblastoma to form and grow into an aggressive tumor. However, when it comes to resistance, it’s not primarily about genetic changes, but rather about cells rapidly adapting their behavior. The reason that embryonic tumor cells are less responsive to drugs is not yet fully understood, but researchers believe that cells in their immature state can adapt and survive under changing conditions.

“Current chemotherapy treatment targets rapidly dividing tumor cells. The results of our research may contribute to new treatments that better reach the whole tumor, in order to avoid the development of resistance. In future research, it It will be important to understand how to specifically target the embryonic state of the neuroblastoma cell in order to cure patients”, concludes Daniel Bexell.

(With ANI entries)

Disclaimer: This post was auto-published from an agency feed without any text editing and has not been reviewed by an editor

Open in app